DakoCytomation Acquires Gastric Ulcer Test
By HospiMedica staff writers
Posted on 15 Sep 2003
The rights to a test detecting the ulcer-causing bacteria Helicobactor pylori have been acquired by DakoCytomation (Copenhagen, Denmark) from Connex GmbH (Martinsried, Germany), a biotechnology company.Posted on 15 Sep 2003
According to the agreement, DakoCytomation will handle continued production, sales, distribution, and customer service of the test, which will become part of DakoCytomation's diagnostic portfolio. The H pylori antibodies are used in a test that is an enzyme-linked immunosorbent assay (ELISA). Compared to other tests, this method is noninvasive and because it is cost effective, more patients will be able to receive optimal treatment, states DakoCytomation.
"Acquisition of the H pylori rights is strategically important to us; we continuously aim at expanding and strengthening our proprietary pool of key intellectual property rights to better serve our customers and secure our continued development and growth,” said Erik Winther, executive vice president and CFO of DakoCytomation.
Related Links:
DakoCytomation
Connex
.jpg)
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
New
Urine Analyzer
respons® UDS100
